The new National Comprehensive Cancer Network (NCCN) Guidelines for non-small cell lung cancer (NSCLC) added lorlatinib as a ROS1 treatment option, after progression on crizotinib or ceritinib. This means most insurance should start covering lorlatinib for ROS1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (Version 2.2019) (subscription required, but … Continue reading NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC
“Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved LORBRENA® [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or … Continue reading U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC
Lung Cancer Canada is collecting data to support approval of crizotinib for ROS1+ non-small cell lung cancer in their country. Their deadline for submission is rapidly approaching, and they need more data to strengthen their case. They would like ROS1+ patients who have taking crizotinib to share the following information (no names): Demographic data (e.g., … Continue reading ATTENTION ALL ROS1+ CANCER PATIENTS! Canadian ROS1 patients need our help ASAP!
The ROS1ders received the information below directly from the researcher, and agreed to share it in hopes patients with ROS1+ NSCLC would participate. We receive no compensation of any kind for sharing this information. ————————————- INVITATION TO PARTICIPATE IN RESEARCH STUDY “The Lived-Experience and Needs of Lung Cancer Patients with Driver Mutations” We invite you … Continue reading ROS1+ lung cancer patients: Paid opportunity to share your experience for research
Members of The ROS1ders will be attending The International Association for the Study of Lung Cancer’s (IASLC) annual World Conference on Lung Cancer (WCLC) in Toronto, Canada, September 23-26, 2018. The Twitter hashtag for the conference is #WCLC2018. Presentations that will mention ROS1+ cancer are listed below. The abstract book containing these and other WCLC … Continue reading Presentations on ROS1+ Cancer at IASLC #WCLC2018
“No testing methodology demonstrated 100% sensitivity in the detection of ROS1 rearrangements or fusions among patients with non-small cell lung cancer, according to study results.” “The main point is just to be aware of the deficiencies in these assays and not to always trust a negative result from a single test,” Kurtis D. Davies, PhD, … Continue reading Detection of ROS1 rearrangement in lung cancer remains “complex”